Studies on the Effectiveness and Safety of Cilostazol, Beraprost Sodium, Prostaglandin E1 for the Treatment of Intermittent Claudication

DOI Web Site Web Site PubMed 参考文献39件
  • HASHIGUCHI Masayuki
    Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University Division for Evaluation and Analysis of Drug Information, Center of Clinical Pharmacy and Clinical Sciences, School of Pharmaceutical Sciences, Kitasato University
  • OHNO Keiko
    Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University
  • SAITO Ryoko
    Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University

書誌事項

タイトル別名
  • Studies on the Effectiveness and Safety of Cilostazol, Beraprost Sodium, Prostaglandin E<sub>1</sub> for the Treatment of Intermittent Claudication

この論文をさがす

説明

  To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E1 (PGE1), by using a systemic review of literature and a meta-analysis. A search was undertaken for studies reported between 1966—2002 in the MEDLINE database, and references in published articles and reviews were obtained. Data for maximum walking distance (MWD), pain-free walking distance (PFWD), and adverse clinical events were extracted from the articles that met the inclusion criteria. The pooled estimates of the weighted mean differences (WMD) of MWD and PFWD for cilostazol were 52.19 m [95% confidence interval (CI) 32.08, 72.31] and 39.75 m [95% CI 23.39, 56.10], and those for PGE1 were 100.27 m [95% CI 15.76, 184.78] and 55.73 [95% CI 21.54, 89.92], respectively. These differences were statistically significant between the test drugs and placebo. However there was no statistical significance difference between beraprost sodium and placebo, even though there was one study that showed a tendency for improvement in walking distance. The total rate of adverse clinical events in cilostazol and beraprost sodium was higher than that for placebo, while there was no statistical significant difference between PGE1 and placebo, although PGE1 had a higher tendency for adverse clinical events. The literature evaluation results and the meta-analysis suggest that these two drugs (cilostazol and PGE1) can be considered to be effective drugs for the treatment of IC. Due to current availability of only a few clinical reports, further studies are needed to clarify the efficacy of beraprost sodium in the treatment of IC.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 124 (6), 321-332, 2004-06-01

    公益社団法人 日本薬学会

参考文献 (39)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ